| A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors M Bacac, T Fauti, J Sam, S Colombetti, T Weinzierl, D Ouaret, W Bodmer, ... Clinical Cancer Research 22 (13), 3286-3297, 2016 | 345 | 2016 |
| Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3 TH Schaller, KA Batich, CM Suryadevara, R Desai, JH Sampson Expert review of clinical immunology 13 (11), 1049-1060, 2017 | 115 | 2017 |
| Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors AC Guidon, LB Burton, BK Chwalisz, J Hillis, TH Schaller, AA Amato, ... Journal for immunotherapy of cancer 9 (7), 2021 | 114 | 2021 |
| In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell … S Lehmann, R Perera, HP Grimm, J Sam, S Colombetti, T Fauti, L Fahrni, ... Clinical Cancer Research 22 (17), 4417-4427, 2016 | 68 | 2016 |
| A rationally designed fully human EGFRvIII: CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma PC Gedeon, TH Schaller, SK Chitneni, BD Choi, CT Kuan, ... Clinical Cancer Research 24 (15), 3611-3631, 2018 | 47 | 2018 |
| Advances and challenges: dendritic cell vaccination strategies for glioblastoma TH Schaller, JH Sampson Expert review of vaccines 16 (1), 27-36, 2017 | 47 | 2017 |
| Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data KL Reynolds, S Arora, RK Elayavilli, WC Louv, TH Schaller, A Khandelwal, ... Journal for ImmunoTherapy of Cancer 9 (7), 2021 | 35 | 2021 |
| First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach TH Schaller, DJ Snyder, I Spasojevic, PC Gedeon, L Sanchez-Perez, ... Journal for Immunotherapy of Cancer 8 (1), 2020 | 23 | 2020 |
| Challenges to using big data in cancer SM Sweeney, HK Hamadeh, N Abrams, SJ Adam, S Brenner, ... Cancer research 83 (8), 1175-1182, 2023 | 17 | 2023 |
| Pharmacokinetic analysis of a novel human EGFRvIII: CD3 bispecific antibody in plasma and whole blood using a high-resolution targeted mass spectrometry approach TH Schaller, MW Foster, JW Thompson, I Spasojevic, D Normantaite, ... Journal of proteome research 18 (8), 3032-3041, 2019 | 13 | 2019 |
| GLP toxicology study of a fully-human T cell redirecting CD3: EGFRvIII binding immunotherapeutic bispecific antibody PC Gedeon, MA Streicker, TH Schaller, GE Archer, MP Jokinen, ... Plos one 15 (7), e0236374, 2020 | 6 | 2020 |
| High throughput screening of valganciclovir in acidic microenvironments of polyester thin films T Schaller, T Wenner, R Agrawal, S Teoh, LT Phua, JSC Loo, TWJ Steele Materials 8 (4), 1714-1728, 2015 | 6 | 2015 |
| (2016a) S Lehmann, R Perera, HP Grimm, J Sam, S Colombetti, T Fauti, L Fahrni, ... vivo fluorescence imaging of the activity of CEA TCB, a novel T-cell …, 0 | 2 | |
| Consensus disease definitions for the spectrum of neurologic immune related adverse events. AC Guidon, LB Burton, BK Chwalisz, JM Hillis, T Schaller, KL Reynolds, ... Journal of Clinical Oncology 39 (15_suppl), 2647-2647, 2021 | 1 | 2021 |
| Abstract A80: The effects of CCL3 on dendritic cell migration and immune cell activation TH Schaller, KA Batich, K Hotchkiss, X Cui, L Sanchez-Perez, ... Cancer Immunology Research 8 (4_Supplement), A80-A80, 2020 | 1 | 2020 |
| Bench to Bedside: A Bispecific Antibody for Treating Brain Tumors TH Schaller Duke University, 2019 | 1 | 2019 |
| Immu-23. Antigen-Specific Effector Memory Cd4+ T Cells and Ccl3 Potentiate Dendritic Cell Vaccines and Antitumor Immunity K Batich, L Sanchez-Perez, T Schaller, X Cui, W Xie, G Archer, P Norberg, ... Neuro-Oncology 20 (suppl_6), vi126-vi126, 2018 | 1 | 2018 |
| Introduction to Translational Immunotherapy for Brain Tumors AM Swartz, TH Schaller, JH Sampson Translational Immunotherapy of Brain Tumors, xiii-xxix, 2017 | 1 | 2017 |
| Immunotherapy for High-Grade Gliomas TH Schaller, JH Sampson Malignant Brain Tumors: State-of-the-Art Treatment, 177-192, 2017 | 1 | 2017 |
| EXTH-82. T CELL HITCHHIKING AS A MECHANISM OF DRUG DELIVERY TO THE BRAIN K Singh, P Gedeon, T Schaller, D Snyder, M Khasraw, J Sampson Neuro-Oncology 23 (Suppl 6), vi182, 2021 | | 2021 |
John H. Sampson, M.D., Ph.D., M.H.Sc...Wilkins Distinguished Professor and Chief of NeurosurgeryVerified email at duke.edu
